microRNA BIOMARKER FOR EARLY DIAGNOSIS OF MILD COGNITIVE IMPAIRMENT OR ALZHEIMER TYPE DEMENTIA

A microRNA biomarker is for early diagnosis of mild cognitive impairment or Alzheimer type dementia. The microRNA biomarker includes miRNAs of SEQ ID NOs: 1 to 5 obtained by molecule-based analysis are expressed in the blood plasma of patients with mild cognitive impairment or Alzheimer type dementi...

Full description

Saved in:
Bibliographic Details
Main Authors PARK, TAE JU, KIM, MYEONG OK, PARK, HYUN YOUNG
Format Patent
LanguageEnglish
Published 24.10.2024
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS OR TEST PAPERS THEREFOR
CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES
ENZYMOLOGY
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS
METALLURGY
MICROBIOLOGY
MUTATION OR GENETIC ENGINEERING
PROCESSES OF PREPARING SUCH COMPOSITIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:A microRNA biomarker is for early diagnosis of mild cognitive impairment or Alzheimer type dementia. The microRNA biomarker includes miRNAs of SEQ ID NOs: 1 to 5 obtained by molecule-based analysis are expressed in the blood plasma of patients with mild cognitive impairment or Alzheimer type dementia. The miRNAs have an effect of reducing the expression of proteins that are related to mild cognitive impairment or Alzheimer type dementia. As such, the early diagnosis of mild cognitive impairment or Alzheimer type dementia is enabled before symptoms appear by utilizing a novel miRNA present in relatively non-invasive blood plasma as a diagnostic indicator.
Bibliography:Application Number: US202218682176